Skip to main content
Top

07-05-2021 | ADA 2021 | Conference coverage | News

AMPLITUDE-M: Improved glycemic and weight outcomes with efpeglenatide vs placebo

Author: Eleanor McDermid

print
PRINT
insite
SEARCH

medwireNews: Treatment with efpeglenatide significantly improves glycemic control and results in weight loss for medication-naïve people with type 2 diabetes, report the AMPLITUDE-M researchers.

Juan Frías (National Research Institute, Los Angeles, USA) presented the findings at the virtual ADA 81st Scientific Sessions. In response to an audience question, he said a decision about whether to submit efpeglenatide for regulatory approval had yet to be made, and would depend in part on the results of the cardiovascular outcomes trial AMPLITUDE-O. These were later reported to be positive.

AMPLITUDE-M involved 406 people with type 2 diabetes of around 5 years’ duration, treated with diet and exercise, who had a glycated hemoglobin (HbA1c) level between 7.0% and 10.0% (53 and 86 mmol/mol).

During 30 weeks of treatment, including a dose-escalation period of up to 4 weeks, the average HbA1c level fell from 8.1% (65 mmol/mol) to 6.9%, 6.6%, and 6.4% (52, 49, and 46 mmol/mol) in participants randomly assigned to take 2, 4, and 6 mg/week efpeglenatide, respectively.

These levels represented significant improvements of 0.51%, 0.83%, and 1.04%, respectively, compared with the change in the placebo group, and the reductions were maintained during an additional 26 weeks of treatment.

Up to 73.8% of people taking efpeglenatide achieved HbA1c levels below 7.0%, compared with 25.5% of the placebo group. The corresponding rates for HbA1c below 6.5% (48 mmol/mol) were 58.3% and 8.8%.

Participants taking efpeglenatide 2 mg/week did not achieve a significant weight reduction versus placebo, but those taking 4 and 6 mg/week achieved weight reductions averaging 3.2 kg more than that in the placebo group.

The weight loss in the 4 mg group was maintained until week 56. By contrast, the average weight of the 6 mg group increased until it was close to that of the placebo group, although Frías noted this was largely explained by a single trial participant gaining 22 kg in that time.

The safety profile of efpeglenatide was as expected for a medication from the glucagon-like peptide-1 receptor agonist class, with diarrhea, nausea, and vomiting the most frequent events.

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group

ADA Scientific Sessions; 25–29 June 2021

print
PRINT

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »